ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 102

Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms

Julian F. Oviedo1, Elena N. Cravens1 and Vaishali R. Moulton2,3, 1Beth Israel Deaconess Medical Center, Harvard Medical School, Medicine/Rheumatology, Boston, MA, 2Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, 3Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Gene Expression, SLE, T cells and hormones

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic lupus erythematosus (SLE) is a chronic debilitating autoimmune disease that primarily afflicts women in the childbearing years. Female hormones especially estrogen are implicated in the pathogenesis of disease, however the precise molecular mechanisms regulated by estrogen in immune cells are not well understood. We previously identified novel roles for the multifunctional protein serine/arginine-rich splicing factor 1 (SRSF1) in T cells. We showed that SRSF1 promotes expression of the CD3zeta signaling gene and activates IL-2 production in normal T cells. T cell specific Srsf1-conditional knockout mice exhibit defects in T cell function and develop autoimmune disease. SRSF1 expression levels are decreased in T cells from SLE patients, and associate with severe disease activity. Importantly, overexpression of SRSF1 into SLE T cells rescues IL-2 production. These results imply that the SRSF1 is an important molecule in T cells and immune-mediated disease. However, not much is known about the regulation of SRSF1, and if hormones may contribute to its expression.

Methods:

Peripheral blood was collected from healthy women in the follicular phase of the menstrual cycle. T cells were isolated by negative selection from peripheral blood. T cells were cultured (in RPMI without phenol red supplemented with charcoal-stripped serum), with increasing concentrations (0, 1nM, 10nM, 100nM) of beta-estradiol for 18 – 24 hours. To assess mRNA stability, transcription was blocked with actinomycin D, cells collected at 0, 0.5, 1, 1.5 and 2 hours, and Srsf1expression assessed by RT-qPCR. To assess posttranslational protein degradation mechanisms, the proteasome inhibitor MG132 or the lysosome inhibitor Bafilomycin A1 were added to cultures followed by western blots for SRSF1. The Srsf1 promoter was cloned into a pGL3-luciferase plasmid. T cells were transfected by electroporation and luciferase activity measured by a luminometer.

Results:

Exposure to estrogen led to a dose dependent increase in Srsf1 mRNA expression, but decreased protein levels in T cells. This discrepancy between mRNA and protein levels suggests that estrogen controls SRSF1 at transcriptional and post-transcriptional levels and may upregulate transcriptional activity of its promoter but downregulate protein levels via mRNA decay, translation or protein degradation.Accordingly, estrogen increased luciferase activity of the Srsf1 promoter-luciferase construct indicating that estrogen activates Srsf1 transcription. Estrogen did not affect mRNA stability, however protein analyses showed that the proteasome is involved in the degradation of SRSF1. In silico analysis revealed microRNA (miR) target sites within the Srsf13`UTR, of which miR-21-5p, miR-27, and miR-200b-3p are known to be regulated by estrogen and to be dysregulated in SLE.

Conclusion:

Our results suggest that estrogen can modulate the expression of SRSF1 via transcriptional and posttranscriptional mechanisms in human T lymphocytes, thus revealing a potential molecular link between hormones, immune cells and autoimmune disease.


Disclosure: J. F. Oviedo, None; E. N. Cravens, None; V. R. Moulton, None.

To cite this abstract in AMA style:

Oviedo JF, Cravens EN, Moulton VR. Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/estrogen-controls-the-expression-of-serine-arginine-rich-splicing-factor-1-srsf1-in-human-t-lymphocytes-via-transcriptional-and-post-transcriptional-mechanisms/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/estrogen-controls-the-expression-of-serine-arginine-rich-splicing-factor-1-srsf1-in-human-t-lymphocytes-via-transcriptional-and-post-transcriptional-mechanisms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology